]>
IRCT20210408050895N1 IRCT 2021-06-20 Rasht University of Medical Sciences To determine the impact oral Acetazolamide in changing short time intraocular pressure (IOP) fluctuation in intra vitreous bevacizumab injection A comparison changing short time intraocular pressure (IOP) fluctuation in intravitreal bevacizumab injection with and without acetazolamide oral drug in amir almomenin hospital, A clinical trial study 2021-06-20 anticipated 340 Complete https://irct.ir/trial/55501 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients who were included were assigned randomly in 2 groups. Group A: patients receiving oral Acetazolamide 250 mg half hour time before intra vitreous Bevacizumab injection. Group B: patients with no receiving oral Acetazolamide before intra vitreous Bevacizumab injection The ward nurse randomly and without information from primary disease of patient give half of them oral Acetazolamide 250mg and half of them not receiving oral Acetazolamid and then entering groups. 1 all of the patients with a eye disease need to intravitreous bevacizumab injection. Intervention 1: Intervention group: Patients in Intervention groups at first measuring intraocular pressure with Tonometry slit lamp. Then receiving oral Acetazolamide 250mg , 30 minutes before intravitreous bevacizumab injection and then 2-3 hours after intravitreous bevacizumab Injection measuring Intraocular pressure with Tonometry and compared with control group. Intervention 2: Control group: Patients in Control groups at first measuring Intraocular pressure with Tonometry slit lamp. Before intravitreous bevacizumab Injection and no Receiving oral Acetazolamide and then 2-3 hours after intravitreous bevacizumab Injection Remeasuring Intraocular pressure with Tonometry slit lamp and compared with Intervention group. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is It should be done in consultation with the group members and the tutor.
public Hasan Behboudi
Amiralmomenin Hospital, 17 Shahrivar St., Rasht, Guilan, Iran
Rasht Iran (Islamic Republic of) 4136937459 +98 13 3323 6886 behboudi_dr@yahoo.com Rasht University of Medical Sciences scientific Hasan Behboudi
Eye Research Center, Department of Eye, Amiralmomenin Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Rasht Iran (Islamic Republic of) 4136937459 +98 13 3323 6886 behboudi_dr@gmail.com Rasht University of Medical Sciences Iran (Islamic Republic of) all of the patients with a eye disease need to intra vitreous bevacizumab injection in amiralmomnin hospital no limit no limit Both patients with a history of glaucoma ΒΈ glaucoma surgery scleral buckle ( SB) deep vitrectomy (Vitx) iris neovascularization (NI) history of anti-glaucoma drug Treatment - Drugs N/A Intervention group: Patients in Intervention groups at first measuring intraocular pressure with Tonometry slit lamp. Then receiving oral Acetazolamide 250mg , 30 minutes before intravitreous bevacizumab injection and then 2-3 hours after intravitreous bevacizumab Injection measuring Intraocular pressure with Tonometry and compared with control group. Control group: Patients in Control groups at first measuring Intraocular pressure with Tonometry slit lamp. Before intravitreous bevacizumab Injection and no Receiving oral Acetazolamide and then 2-3 hours after intravitreous bevacizumab Injection Remeasuring Intraocular pressure with Tonometry slit lamp and compared with Intervention group Intraocular pressure. Timepoint: half an hour before injecting bevacizumab in vitrous and three hours after injection. Method of measurement: Tonometer Asylum Lamp. Rasht University of Medical Sciences Approved 2021-02-17 Ethics committee of Giulan University of Medical Sciences Amiralmomenin Hospital, 17 Shahrivar St., Rasht, Guilan, Iran Rasht Guilan Iran (Islamic Republic of)